IL89770A - Analgesic peptides and pharmaceutical compositions containing them and the process for the preparation of some such compounds - Google Patents

Analgesic peptides and pharmaceutical compositions containing them and the process for the preparation of some such compounds

Info

Publication number: IL89770A
Authority: IL; Israel
Prior art keywords: pro; lys; peptide; arg; val
Prior art date: 1988-03-28

Application number

IL8977089A

Other languages

English (en)

Original Assignee

British Tech Group

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-03-28

Filing date

1989-03-28

Publication date

1994-12-29

1988-03-28 Priority claimed from GB888807427A external-priority patent/GB8807427D0/en

1989-03-28 Application filed by British Tech Group filed Critical British Tech Group

1994-12-29 Publication of IL89770A publication Critical patent/IL89770A/en

Links

238000002360 preparation method Methods 0.000 title claims abstract description 14
238000000034 method Methods 0.000 title claims description 15
150000001875 compounds Chemical class 0.000 title claims description 9
239000008194 pharmaceutical composition Substances 0.000 title claims description 7
230000008569 process Effects 0.000 title claims description 6
101500007657 Crotalus durissus terrificus Crotoxin chain gamma Proteins 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 103
150000001408 amides Chemical group 0.000 claims abstract description 28
150000003839 salts Chemical class 0.000 claims abstract description 27
210000004899 c-terminal region Anatomy 0.000 claims abstract description 26
238000011282 treatment Methods 0.000 claims abstract description 19
125000000539 amino acid group Chemical group 0.000 claims abstract description 10
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 6
230000036407 pain Effects 0.000 claims abstract description 6
LQJAALCCPOTJGB-YUMQZZPRSA-N Arg-Pro Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O LQJAALCCPOTJGB-YUMQZZPRSA-N 0.000 claims abstract description 4
108010065920 Insulin Lispro Proteins 0.000 claims abstract description 4
AIXUQKMMBQJZCU-IUCAKERBSA-N Lys-Pro Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O AIXUQKMMBQJZCU-IUCAKERBSA-N 0.000 claims abstract description 4
AFLBTVGQCQLOFJ-AVGNSLFASA-N Lys-Pro-Arg Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O AFLBTVGQCQLOFJ-AVGNSLFASA-N 0.000 claims abstract description 4
108010029539 arginyl-prolyl-proline Proteins 0.000 claims abstract description 4
230000002265 prevention Effects 0.000 claims abstract description 4
LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 claims description 25
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 13
YSPZCHGIWAQVKQ-AVGNSLFASA-N Lys-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCCN YSPZCHGIWAQVKQ-AVGNSLFASA-N 0.000 claims description 13
108010060534 MSH (11-13) Proteins 0.000 claims description 11
108010013842 interleukin 1beta (193-195) Proteins 0.000 claims description 11
239000000203 mixture Substances 0.000 claims description 11
125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims description 10
LOGFVTREOLYCPF-RHYQMDGZSA-N Lys-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-RHYQMDGZSA-N 0.000 claims description 10
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical group NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 7
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 7
239000004473 Threonine Substances 0.000 claims description 7
235000008521 threonine Nutrition 0.000 claims description 7
229960002898 threonine Drugs 0.000 claims description 7
-1 Phe Chemical compound 0.000 claims description 6
ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 claims description 5
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 5
239000003085 diluting agent Substances 0.000 claims description 5
125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 4
229960005261 aspartic acid Drugs 0.000 claims description 4
235000003704 aspartic acid Nutrition 0.000 claims description 4
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 3
AWMAZIIEFPFHCP-RCWTZXSCSA-N Arg-Pro-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O AWMAZIIEFPFHCP-RCWTZXSCSA-N 0.000 claims description 3
VUGWHBXPMAHEGZ-SRVKXCTJSA-N Arg-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCN=C(N)N VUGWHBXPMAHEGZ-SRVKXCTJSA-N 0.000 claims description 3
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
239000004480 active ingredient Substances 0.000 claims description 3
229960003767 alanine Drugs 0.000 claims description 3
235000004279 alanine Nutrition 0.000 claims description 3
235000005772 leucine Nutrition 0.000 claims description 3
229960003136 leucine Drugs 0.000 claims description 3
229960001153 serine Drugs 0.000 claims description 3
235000004400 serine Nutrition 0.000 claims description 3
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical group OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 2
235000014705 isoleucine Nutrition 0.000 claims 2
229960000310 isoleucine Drugs 0.000 claims 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 2
235000014393 valine Nutrition 0.000 claims 2
229960004295 valine Drugs 0.000 claims 2
239000004474 valine Substances 0.000 claims 2
239000003814 drug Substances 0.000 abstract description 4
OWSMKCJUBAPHED-JYJNAYRXSA-N Arg-Pro-Tyr Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 OWSMKCJUBAPHED-JYJNAYRXSA-N 0.000 abstract description 3
208000004454 Hyperalgesia Diseases 0.000 description 35
208000035154 Hyperesthesia Diseases 0.000 description 35
230000000694 effects Effects 0.000 description 32
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 29
230000000763 evoking effect Effects 0.000 description 26
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 23
241000700159 Rattus Species 0.000 description 23
238000004128 high performance liquid chromatography Methods 0.000 description 20
102000004196 processed proteins & peptides Human genes 0.000 description 20
150000001413 amino acids Chemical group 0.000 description 19
235000001014 amino acid Nutrition 0.000 description 17
229940024606 amino acid Drugs 0.000 description 17
230000000917 hyperalgesic effect Effects 0.000 description 17
229960002986 dinoprostone Drugs 0.000 description 16
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 16
238000004458 analytical method Methods 0.000 description 15
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 15
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
229960000905 indomethacin Drugs 0.000 description 14
230000035484 reaction time Effects 0.000 description 13
239000011347 resin Substances 0.000 description 13
229920005989 resin Polymers 0.000 description 13
230000004044 response Effects 0.000 description 13
108010002352 Interleukin-1 Proteins 0.000 description 10
239000007924 injection Substances 0.000 description 10
238000002347 injection Methods 0.000 description 10
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 10
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
241001465754 Metazoa Species 0.000 description 9
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 9
239000002904 solvent Substances 0.000 description 8
238000003786 synthesis reaction Methods 0.000 description 8
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
239000002253 acid Substances 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
229960002240 iloprost Drugs 0.000 description 7
HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 description 7
230000003389 potentiating effect Effects 0.000 description 7
125000001433 C-terminal amino-acid group Chemical group 0.000 description 6
101100512078 Caenorhabditis elegans lys-1 gene Proteins 0.000 description 6
241000699670 Mus sp. Species 0.000 description 6
230000000202 analgesic effect Effects 0.000 description 6
239000000679 carrageenan Substances 0.000 description 6
229940113118 carrageenan Drugs 0.000 description 6
235000010418 carrageenan Nutrition 0.000 description 6
229920001525 carrageenan Polymers 0.000 description 6
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 6
210000005087 mononuclear cell Anatomy 0.000 description 5
229960005181 morphine Drugs 0.000 description 5
239000007790 solid phase Substances 0.000 description 5
LUTDBHBIHHREDC-IHRRRGAJSA-N Lys-Pro-Lys Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O LUTDBHBIHHREDC-IHRRRGAJSA-N 0.000 description 4
229940035676 analgesics Drugs 0.000 description 4
239000005557 antagonist Substances 0.000 description 4
239000000730 antalgic agent Substances 0.000 description 4
238000001514 detection method Methods 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
150000002500 ions Chemical class 0.000 description 4
230000003902 lesion Effects 0.000 description 4
239000012071 phase Substances 0.000 description 4
238000010532 solid phase synthesis reaction Methods 0.000 description 4
238000001228 spectrum Methods 0.000 description 4
230000003637 steroidlike Effects 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
108010016626 Dipeptides Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
239000004472 Lysine Substances 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
125000003368 amide group Chemical group 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
229940079593 drug Drugs 0.000 description 3
230000002496 gastric effect Effects 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
238000010647 peptide synthesis reaction Methods 0.000 description 3
125000006239 protecting group Chemical group 0.000 description 3
230000007017 scission Effects 0.000 description 3
MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
QUYCUALODHJQLK-CIUDSAMLSA-N Lys-Asp-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O QUYCUALODHJQLK-CIUDSAMLSA-N 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
239000000556 agonist Substances 0.000 description 2
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
230000008485 antagonism Effects 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
230000002146 bilateral effect Effects 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
125000004744 butyloxycarbonyl group Chemical group 0.000 description 2
238000009833 condensation Methods 0.000 description 2
230000005494 condensation Effects 0.000 description 2
239000000470 constituent Substances 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
238000010511 deprotection reaction Methods 0.000 description 2
239000002158 endotoxin Substances 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
239000000178 monomer Substances 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
210000000929 nociceptor Anatomy 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
150000003180 prostaglandins Chemical class 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000006104 solid solution Substances 0.000 description 2
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical class CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
VUCNQOPCYRJCGQ-UHFFFAOYSA-N 2-[4-(hydroxymethyl)phenoxy]acetic acid Chemical class OCC1=CC=C(OCC(O)=O)C=C1 VUCNQOPCYRJCGQ-UHFFFAOYSA-N 0.000 description 1
WHNPOQXWAMXPTA-UHFFFAOYSA-N 3-methylbut-2-enamide Chemical compound CC(C)=CC(N)=O WHNPOQXWAMXPTA-UHFFFAOYSA-N 0.000 description 1
108010040819 BW 443C Proteins 0.000 description 1
239000004971 Cross linker Substances 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
102100025027 E3 ubiquitin-protein ligase TRIM69 Human genes 0.000 description 1
206010017865 Gastritis erosive Diseases 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
101000830203 Homo sapiens E3 ubiquitin-protein ligase TRIM69 Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
BXIXBSNBJITKTA-XUGSSHSWSA-N acetic acid;(2s)-n-[2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]-1-[(2s)-2-amino-3-(4-nitrophenyl)propanoyl]pyrrolidine-2-carboxamide Chemical compound CC(O)=O.CC(O)=O.C([C@H](N)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(=CC=1)[N+]([O-])=O)C1=CC=C(O)C=C1 BXIXBSNBJITKTA-XUGSSHSWSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
150000003862 amino acid derivatives Chemical class 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
238000005915 ammonolysis reaction Methods 0.000 description 1
230000036592 analgesia Effects 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000001754 anti-pyretic effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
244000309466 calf Species 0.000 description 1
150000001734 carboxylic acid salts Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
229960001760 dimethyl sulfoxide Drugs 0.000 description 1
ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
229940120889 dipyrone Drugs 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 1
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000036441 nociceptive stimulation Effects 0.000 description 1
108091008700 nociceptors Proteins 0.000 description 1
ODBDXKPHRXKFCM-UHFFFAOYSA-N octa-1,4,7-triene-3,6-dione Chemical group C=CC(=O)C=CC(=O)C=C ODBDXKPHRXKFCM-UHFFFAOYSA-N 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
230000007170 pathology Effects 0.000 description 1
125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
150000003815 prostacyclins Chemical class 0.000 description 1
230000002997 prostaglandinlike Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
238000000746 purification Methods 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
239000002516 radical scavenger Substances 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
230000020341 sensory perception of pain Effects 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Pain & Pain Management (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Genetics & Genomics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IL8977089A 1988-03-28 1989-03-28 Analgesic peptides and pharmaceutical compositions containing them and the process for the preparation of some such compounds IL89770A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB888807427A GB8807427D0 (en)	1988-03-28	1988-03-28	Peptides
GB888828833A GB8828833D0 (en)	1988-03-28	1988-12-09	Peptides

Publications (1)

Publication Number	Publication Date
IL89770A true IL89770A (en)	1994-12-29

Family

ID=26293705

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL8977089A IL89770A (en)	1988-03-28	1989-03-28	Analgesic peptides and pharmaceutical compositions containing them and the process for the preparation of some such compounds

Country Status (12)

Country	Link
EP (1)	EP0335662B1 (de)
JP (2)	JP2633369B2 (de)
AT (1)	ATE125548T1 (de)
CA (1)	CA1340186C (de)
DE (1)	DE68923572T2 (de)
FI (1)	FI95273C (de)
GB (1)	GB2217331C (de)
HK (1)	HK45895A (de)
IE (1)	IE61222B1 (de)
IL (1)	IL89770A (de)
NO (1)	NO300978B1 (de)
WO (1)	WO1989009226A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2633369B2 (ja)	1988-03-28	1997-07-23	ブリティッシュ・テクノロジー・グループ・リミテッド	ペプチド
IL99527A (en) *	1990-09-28	1997-08-14	Lilly Co Eli	Tripeptide antithrombotic agents
IT1277841B1 (it) *	1995-04-19	1997-11-12	Molteni & C Dei Fratelli Alitt	Ammine dotate di attivita' analgesica, loro preparazione e uso
FR2738746B1 (fr) *	1995-09-19	1997-11-14	Oreal	Utilisation d'au moins un peptide dans une composition cosmetique ou pour la preparation d'un medicament
US7402559B2 (en)	1999-03-24	2008-07-22	Msh Pharma, Incorporated	Composition and method of treatment for urogenital conditions
WO2000059527A1 (en) *	1999-03-24	2000-10-12	Zengen, Inc.	Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone
DE10106852A1 (de)	2001-02-14	2002-09-05	T Luger	Entzündungshemmende Verbindungen
AU2014323008B2 (en) *	2013-09-23	2018-02-08	Dr. August Wolff Gmbh & Co. Kg Arzneimittel	Anti-inflammatory tripeptides
EP3065756B1 (de)	2013-11-07	2019-02-20	Dr. August Wolff GmbH & Co. KG Arzneimittel	Lagerstabile lyophilisierte tripeptidformulierungen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3778426A (en) *	1970-12-16	1973-12-11	Research Corp	Therapeutically useful polypeptides
IT8021120A0 (it) *	1979-04-02	1980-04-01	Inst Organicheskogo Sinteza Ak	Analogo ciclico del peptide naturale stimolante la fagocitosi: treonile-ciclo (n-lisile-prolile-arginile).
US4377515A (en) *	1979-10-01	1983-03-22	Merck & Co., Inc.	Long lasting agonists and antagonists of LH-RH
US4585757A (en) *	1984-07-27	1986-04-29	Texas Tech University Health Sciences Center	Hypotensive active peptides
AU602483B2 (en) *	1985-01-18	1990-10-18	Immunetech Pharmaceuticals	Immunoregulatory peptides
JP2633369B2 (ja)	1988-03-28	1997-07-23	ブリティッシュ・テクノロジー・グループ・リミテッド	ペプチド

1989
- 1989-03-28 JP JP1503798A patent/JP2633369B2/ja not_active Expired - Lifetime
- 1989-03-28 DE DE68923572T patent/DE68923572T2/de not_active Expired - Fee Related
- 1989-03-28 WO PCT/GB1989/000319 patent/WO1989009226A1/en not_active Ceased
- 1989-03-28 CA CA000594884A patent/CA1340186C/en not_active Expired - Fee Related
- 1989-03-28 AT AT89303054T patent/ATE125548T1/de not_active IP Right Cessation
- 1989-03-28 GB GB8906972A patent/GB2217331C/en not_active Expired - Fee Related
- 1989-03-28 EP EP89303054A patent/EP0335662B1/de not_active Expired - Lifetime
- 1989-03-28 IL IL8977089A patent/IL89770A/en not_active IP Right Cessation
- 1989-03-29 IE IE99889A patent/IE61222B1/en not_active IP Right Cessation
- 1989-11-27 FI FI895675A patent/FI95273C/fi not_active IP Right Cessation
- 1989-11-27 NO NO894720A patent/NO300978B1/no not_active IP Right Cessation
1995
- 1995-03-30 HK HK45895A patent/HK45895A/xx not_active IP Right Cessation
1996
- 1996-07-23 JP JP8193524A patent/JP2781782B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DE68923572D1 (de)	1995-08-31
JPH09165400A (ja)	1997-06-24
AU3363789A (en)	1989-10-16
HK45895A (en)	1995-04-07
JP2633369B2 (ja)	1997-07-23
NO894720L (no)	1990-01-29
GB2217331B (en)	1991-12-11
GB8906972D0 (en)	1989-05-10
ATE125548T1 (de)	1995-08-15
IE890998L (en)	1989-09-28
JPH02504280A (ja)	1990-12-06
GB2217331A (en)	1989-10-25
EP0335662A1 (de)	1989-10-04
NO300978B1 (no)	1997-08-25
EP0335662B1 (de)	1995-07-26
JP2781782B2 (ja)	1998-07-30
FI895675A0 (fi)	1989-11-27
FI95273C (fi)	1996-01-10
DE68923572T2 (de)	1996-01-18
WO1989009226A1 (en)	1989-10-05
FI95273B (fi)	1995-09-29
GB2217331C (en)	1994-11-16
CA1340186C (en)	1998-12-15
IE61222B1 (en)	1994-10-19
AU629826B2 (en)	1992-10-15
NO894720D0 (no)	1989-11-27

Legal Events

Date	Code	Title
1997-06-10	FF	Patent granted
1998-02-08	KB	Patent renewed
1999-08-17	KB	Patent renewed
2003-12-10	RH1	Patent not in force

Publication	Publication Date	Title
JP4006021B2 (ja)	2007-11-14	ケモカインの生物学的活性の強化法
JP3266311B2 (ja)	2002-03-18	新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
SK83995A3 (en)	1996-09-04	New peptides
EP0647656B1 (de)	2000-05-31	Dem Motilin ähnliche Peptide mit hemmender Wirkung auf den gastrointestinalem Trakt
JPWO1992004374A1 (ja)	1992-09-03	新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
JPH07324097A (ja)	1995-12-12	インターロイキン６拮抗剤、及びペプチド類または医薬として許容されるその塩類
CA1340186C (en)	1998-12-15	Peptides
US5811400A (en)	1998-09-22	Peptide derivatives with δ opioid receptor antagonist or mixed μ agδ antagonist effects
US5580855A (en)	1996-12-03	Peptides
HU185229B (en)	1984-12-28	Process for preparing pharmaceutically active peptides and acetates thereof
EP0755942B1 (de)	1999-08-04	N-amidino- dermorphin-derivat
AU629826C (en)	1994-12-22	Peptides
US5733881A (en)	1998-03-31	Opioid peptide antagonists
EP0101929A1 (de)	1984-03-07	Diester von Polypeptiden, ihre Herstellung und Verwendung
US5215964A (en)	1993-06-01	Peptides useful in regulating the immune and nervous systems
CA2405724C (en)	2010-09-07	Substance p analogs for the treatment of cancer
HK40100630A (zh)	2024-05-03	抗病毒多肽类似物
Śleszyńska et al.	2009	New bradykinin B2 receptor antagonists-influence of C-terminal segment modifications on their pharmacological properties
Sleszyńska et al.	2009	New bradykinin B (2) receptor antagonists-influence of C-terminal segment modifications on their pharmacological properties.
JPH06509571A (ja)	1994-10-27	タキキニン拮抗薬としての環状ヘキサペプチドの製法およびその薬学的化合物
Śleszyńska et al.	0	receptor antagonists—influence of C-terminal segment modifications on their pharmacological properties
JPH10330399A (ja)	1998-12-15	神経伝達ポリペプチド